Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence of Venous Thromboembolism in Critically Ill Coronavirus Disease 2019 Patients Receiving Prophylactic Anticoagulation.

Critical care medicine·2020
Same author

Special Populations: Disaster Care Considerations in Chronically Ill, Pregnant, and Morbidly Obese Patients.

Critical care clinics·2019
Same author

Critical State of Disaster Preparedness.

Critical care clinics·2019
Same author

Engagement and education: care of the critically ill and injured during pandemics and disasters: CHEST consensus statement.

Chest·2014
Same author

Special populations: care of the critically ill and injured during pandemics and disasters: CHEST consensus statement.

Chest·2014
Same author

Critically ill obese and morbidly obese patients. Preface.

Critical care clinics·2010

Related Experiment Video

Updated: Jun 7, 2026

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness
09:17

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness

Published on: May 2, 2017

Cardiovascular considerations in critically ill obese patients.

Mitchell K Craft1, Mary Jane Reed

  • 1Department of Critical Care Medicine, Geisinger Medical Center, 100 North Academy Avenue, Danville, PA 17822, USA.

Critical Care Clinics
|October 26, 2010
PubMed
Summary

Obesity presents complex cardiac challenges, especially in critical care. This article reviews key preventative and therapeutic strategies to manage obesity-related heart conditions.

More Related Videos

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Related Experiment Videos

Last Updated: Jun 7, 2026

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness
09:17

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness

Published on: May 2, 2017

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Critical Care Medicine

Background:

  • Rising global obesity rates contribute to significant cardiovascular disease burden.
  • Obesity exacerbates complex cardiac pathophysiology, particularly in critically ill patients.
  • Effective management strategies are crucial for this growing patient population.

Purpose of the Study:

  • To highlight preventative strategies for obesity-related cardiac conditions.
  • To outline therapeutic approaches for managing cardiac pathophysiology in obese individuals.
  • To provide an overview of critical care management for obese patients with cardiac issues.

Main Methods:

  • Literature review of current research on obesity and cardiac pathophysiology.
  • Analysis of preventative measures and therapeutic interventions.
  • Synthesis of critical care management guidelines for obese patients.

Main Results:

  • Obesity significantly impacts cardiac structure and function.
  • Early intervention and lifestyle modifications are key preventative strategies.
  • Multifaceted therapeutic approaches are required for managing obesity-related cardiac dysfunction.

Conclusions:

  • Addressing obesity-related cardiac pathophysiology is essential for improving patient outcomes.
  • Integrated strategies encompassing prevention and treatment are necessary.
  • Further research is needed to optimize critical care for obese patients with heart conditions.